The phase I study will examine whether high doses of Phytosel, INB Biotechnologies’ proprietary plant-derived oral formulation of selenium, can reduce the negative side effects of two chemotherapeutic drugs. The trial is expected to take approximately one year to complete.
The trial is being conducted at City of Hope in Duarte, California, one of the world’s leading research and treatment centers for cancer, diabetes, HIV/AIDS and other life-threatening diseases.
PhytoSel has been marketed within the nutraceuticals industry for several years as a natural selenium supplement. The micronutrient consists of organic selenium compounds that are produced using INB’s patented hyperaccumulation process.